Orchid, a startup that tests embryos for genetic diseases, has just raised $12 million. "The way that IVF and embryo screening works today is the amount of information available is really limited," Orchid CEO and cofounder Noor Siddiqui said. Genetic testing has been around for years, but it has been usually limited in the diseases it can identify, which include cystic fibrosis, Bloomberg reported. Orchid produces reports with two types of genetic testing: monogenic and polygenic. The cost of the test depends on the number of embryos that Orchid tests.

---

Persons: Noor Siddiqui, Siddiqui, Orchid, Dylan, Anne Wojcicki, Fidji Simo, Peter Kraft Organizations: Business, Bloomberg, Prometheus Fund, Starbloom Capital, One Ventures, Los Angeles Times Locations: San Francisco, Pebblebed